General Information |
| Summary |
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids (CS) vs CS Alone for the Treatment of High-Risk Acute Graft Versus Host Disease |
| Clinical trials phase |
Phase 2 |
| Start date (estimated) |
2023-08-31 |
| End date (estimated) |
2026-12-31 |
| Clinical feature |
| Label |
Graft versus host disease |
| Link |
http://www.orpha.net/ORDO/Orphanet_39812 |
| Description |
A rare disease that occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. Activated donor T cells damage host epithelial cells after an inflammatory cascade that begins with the preparative regimen. |
|
Administrative Information |
| NCT number |
NCT05643638 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05643638 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT05643638 |
| Public contact |
| Email |
clinical@cynata.com |
| Public email |
clinical@cynata.com |
| First name |
Cynata Therapeutics Limited |
| Last name |
Cynata Therapeutics Limited |
| Phone |
+61 3 7067 6940 |
| Country |
|
|
| Sponsors |
Cynata Therapeutics Limited
|
Cells |
| Which differentiated cell type is used |
| Label |
Mesenchymal Stem Cell |
| Link |
http://purl.obolibrary.org/obo/NCIT_C43423 |
| Description |
An undifferentiated stromal cell with the ability to develop into the cells that form distinct mesenchymal tissues; such as bone, muscle, connective tissue, blood vessels, and lymphatic tissue. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
60 |
